Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 98.37 USD -0.61% Market Closed
Market Cap: $6.3B

EV/IC

58.5
Current
47%
More Expensive
vs 3-y average of 39.8

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
58.5
=
Enterprise Value
$5.3B
/
Invested Capital
$95.5m

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
58.5
=
Enterprise Value
$5.3B
/
Invested Capital
$95.5m

Valuation Scenarios

Protagonist Therapeutics Inc is trading above its 3-year average

If EV/IC returns to its 3-Year Average (39.8), the stock would be worth $66.88 (32% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-97%
Maximum Upside
No Upside Scenarios
Average Downside
63%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 58.5 $98.37
0%
3-Year Average 39.8 $66.88
-32%
5-Year Average 38.7 $65.07
-34%
Industry Average 6.9 $11.56
-88%
Country Average 1.5 $2.5
-97%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
6.2B USD 58.5 -47.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -1 260 263.1 -160 127.7
US
Abbvie Inc
NYSE:ABBV
365.2B USD 4.5 87.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 3.6 23
US
Gilead Sciences Inc
NASDAQ:GILD
163.4B USD 3.7 19.2
US
Epizyme Inc
F:EPE
94.1B EUR 966.7 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.7B USD 7.3 27.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.1B USD 5.6 16.5
NL
argenx SE
XBRU:ARGX
41.3B EUR 14.8 37.4
US
Seagen Inc
F:SGT
39.3B EUR 20.8 -61.8
AU
CSL Ltd
ASX:CSL
60.2B AUD 1.5 29.5
P/E Multiple
Earnings Growth PEG
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 34.3
Negative Multiple: -47.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
14%
1.2
NL
argenx SE
XBRU:ARGX
37.4
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.5
9%
3.3

Market Distribution

Higher than 97% of companies in the United States of America
Percentile
97th
Based on 11 657 companies
97th percentile
58.5
Low
0 — 0.9
Typical Range
0.9 — 2.9
High
2.9 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 0.9
Median 1.5
70th Percentile 2.9
Max 566 432.7

Protagonist Therapeutics Inc
Glance View

Market Cap
6.3B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.83 USD
Overvaluation 87%
Intrinsic Value
Price $98.37
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett